Showing results (31-40 of 66) with videos related to
Sort By:
Pageof 7
Mabs|September 26, 2012
IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CAJohn Marquardt, Richard H J Begent, Kerry Chester, et al.Human Molecular Genetics|April 18, 1998
Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic miceC Huxley, E Passage, A M Robertson, et al.Immunotechnology : an International Journal of Immunological Engineering|May 1, 1995
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody libraryR Schier, J D Marks, E J Wolf, et al.Cancer Research|September 1, 1993
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain FvG P Adams, J E McCartney, M S Tai, et al.Nuclear Medicine and Biology|January 12, 2011
Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibodyJason L J Dearling, Stephan D Voss, Patricia Dunning, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.Journal of Immunological Methods|January 29, 2000
Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7Q Zhu, C Zeng, A Huhalov, et al.Bioconjugate Chemistry|February 27, 2015
The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistributionJason L J Dearling, Brett M Paterson, Vamsidhar Akurathi, et al.Journal of Cellular and Molecular Medicine|May 21, 2011
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal originRuth Esser, Tina Müller, Dörthe Stefes, et al.Pageof 7